NMCC Clinical Trials: Recruiting
The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.
Please contact us here for trial details: research@nmohc.com
Clinical Trials
BREAST CANCER STUDIES
MK2870-012: Merck Sharp & Dohme LLC: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery. NCT Identifier NCT06393374
MK2870-011: Merck Sharp & Dohme LLC_TROFUSE-011: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011).
Stemline Therapeutics, Inc_STML-ELA-0422_Elegant: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
TROPION_Breast05_D7630C0001: This is a research study looking at new treatment options for women with a specific type of aggressive breast cancer that has come back (locally recurrent) or spread to other parts of the body (metastatic).
CAMBRIA-2_D8535C00001: AstraZeneca: This study is testing a new medication called Camizestrant (AZD9833) for people with early-stage breast cancer.
TRACY-1_RYZ101-201: RayzeBio, Inc.: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
LUNG CANCER STUDIES
TROPION-Lung17_D763QC00001: A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
TACTI-004: Immutep S.A.S: Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
GS-US-600-6165: Gilead Sciences (LAB85469): Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
PROSTATE CANCER STUDIES
5541-CL-0201: Astellas Pharma Global Development, Inc.: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer. NCT Identifier NCT07005154
BMS rechARge_CA071-1000: Celgene Corporation, a Bristol Myers Squibb Company: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) – recharge
FGCL-3246-112_FibroGen Inc.: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
SKIN CANCER STUDIES
CTP-SCC-03: Alpha Tau Medical LTD.: This study is testing a new treatment option (Alpha DaRT224) for people with skin cancer that has come back (recurrent cutaneous squamous cell carcinoma). Click for more information.
MISCELLANEOUS STUDIES
BEGIN Boston Gene BGER 001: This is a research study looking at the benefits of advanced genetic testing for people with advanced cancer.